VTX-0811 is a human IgG4 monoclonal antibody (mAb) that targets PSGL1/CD162. It modulates immune signaling pathways by enhancing TNF-α/NF-κB and chemokine-mediated signaling while reducing oxidative phosphorylation, fatty acid metabolism, and Myc signaling. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells and exhibits antitumor activity in humanized mouse PDX models of melanoma.